New growth hormone drug ngenla tracked for Long-Term safety in kids
NCT ID NCT05602766
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study follows children with growth hormone deficiency who are starting Ngenla for the first time. Researchers will monitor their growth and any side effects over several years, until November 2027. The goal is to understand the long-term safety and effectiveness of this daily injection in real-world use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ngenla (somatrogon), a growth hormone injection
- What this could lead to
- If successful, this study could confirm that Ngenla is safe and effective for long-term use in children with growth hormone deficiency, supporting its continued use in daily practice.
- What could go wrong
- This is a small, single-patient observational study, not a large controlled trial. Results may not apply to all patients, and long-term risks like glucose disorders or tumors need monitoring.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GROWTH HORMONE DEFICIENCY WITHOUT EPIPHYSEAL CLOSURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan